Marc Kozin Net Worth

The estimated Net Worth of Marc D Kozin is at least $1.74 Milion dollars as of 10 August 2021. Mr. Kozin owns over 3,000 units of Dicerna Pharmaceuticals Inc stock worth over $242,047 and over the last 18 years he sold DRNA stock worth over $1,023,981. In addition, he makes $478,208 as Independent Director at Dicerna Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kozin DRNA stock SEC Form 4 insiders trading

Marc has made over 11 trades of the Dicerna Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of DRNA stock worth $70,980 on 10 August 2021.

The largest trade he's ever made was exercising 16,233 units of Dicerna Pharmaceuticals Inc stock on 6 March 2020 worth over $360,860. On average, Marc trades about 1,376 units every 62 days since 2006. As of 10 August 2021 he still owns at least 6,333 units of Dicerna Pharmaceuticals Inc stock.

You can see the complete history of Mr. Kozin stock trades at the bottom of the page.

Marc Kozin biography

Marc D. Kozin serves as Independent Director of the Company. Mr. Kozin is a professional board member. Previously Mr. Kozin was a career strategy consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 until 2012 and as Senior Advisor from January 2012 to December 2018. Mr. Kozin serves on the Boards of Directors of UFP Technologies, Inc. (NASDAQ: UFPT), HealthCare Royalty Partners, and The Greenlight Fund. Mr. Kozin previously served on the Boards of Directors of CrunchTime! Information Systems, Inc. from 2002 to 2013, Dyax Corp. from January 2012 until January 2016, Frequency Therapeutics, Inc. from 2016 to 2018, OvaScience, Inc. from January 2014 until December 2018, and Endocyte, Inc. from July 2012 until its acquisition by Novartis International AG (NYSE: NVS) in December 2018. Mr. Kozin previously served on the Board of Directors of DukeEngage from 2011 to 2017. Mr. Kozin received his B.A. with distinction, magna cum laude, in Economics from Duke University. He was also awarded an M.B.A. with distinction from The Wharton School, University of Pennsylvania. The Nominating and Corporate Governance Committee believes that Kozin’s substantial experience serving as a board member to biopharmaceutical companies, as well as his business background, provide him with the qualifications and skills to serve as a member of our Board of Directors.

What is the salary of Marc Kozin?

As the Independent Director of Dicerna Pharmaceuticals Inc, the total compensation of Marc Kozin at Dicerna Pharmaceuticals Inc is $478,208. There are 5 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.

How old is Marc Kozin?

Marc Kozin is 58, he's been the Independent Director of Dicerna Pharmaceuticals Inc since 2019. There are 5 older and 7 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.

What's Marc Kozin's mailing address?

Marc's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.

Insiders trading at Dicerna Pharmaceuticals Inc

Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo a Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.

What does Dicerna Pharmaceuticals Inc do?

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.

Complete history of Mr. Kozin stock trades at Chimerix Inc, Dicerna Pharmaceuticals Inc a UFP Technologies

Dicerna Pharmaceuticals Inc executives and stock owners

Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Douglas Fambrough,
  President, Chief Executive Officer, Director
• Robert Ciappenelli,
  Chief Commercial Officer
• Bob Brown,
  Executive Vice President, Research and Development, Chief Scientific Officer
• James Weissman,
  Chief Operating Officer, Executive Vice President
• J. Kevin Buchi,
  Independent Chairman of the Board
• Marc Kozin,
  Independent Director
• Anna Protopapas,
  Independent Director
• Adam Koppel,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Martin Freed,
  Independent Director
• Cynthia Smith,
  Independent Director
• Patrick Gray,
  Independent Director
• Ling Zeng,
  Chief Legal Officer and Secretary
• Shreeram Aradhye,
  Executive Vice President, Chief Medical Officer
• Douglas Pagan,
  Chief Financial Officer
• Stephen Doberstein,
  Independent Director
• Capital Management, Llc Kol...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Theodore Ashburn,
  See Remarks
• John B Green,
  Chief Financial Officer
• David Madden,
  Director
• Pankaj Bhargava,
  Chief Medical Officer
• Viii Associates, L.P.Blair ...,
  
• Bruce Peacock,
  Director
• Ralf Rosskamp,
  Chief Medical Officer
• Brian K Halak,
  Director
• Regina M. Paglia,
  Chief Human Resources Officer
• Capital Life Sciences Inves...,
  
• Capital Management, Llcra C...,
  
• Peter Kolchinsky,
  Director
• Bart W Wise,
  SVP, Legal Affairs
• Dennis Langer,
  Director
• James C Blair,
  10% owner
• Venture Partners V Lp Skyli...,
  
• James E Dentzer,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• James E Deerfield Mgmt L.P....,
  
• Vincent J Miles,
  Director
• Capital Management Llcbrook...,
  
• Kathleen K Schoemaker,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Nicole Vitullo,
  10% owner
• Brian H Dovey,
  10% owner
• Jesse I Treu,
  10% owner
• Viii Associates, L.P. Dp,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner